Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Gossamer Bio to Present at Cantor Global Healthcare Conference

Key Takeaway: Gossamer Bio, Inc. will present at the Cantor Global Healthcare Conference from September 9-11, 2026. The presentation will focus on their clinical-stage product, seralutinib, aimed at treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This event is expected to boost the company's visibility in the healthcare sector.
Price reaction · baseline $0.1756 (2026-09-03 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Gossamer Bio is actively participating in a prominent healthcare conference.
  • The company is focused on a significant therapeutic area, pulmonary hypertension.
  • The presentation may enhance visibility and investor interest in Gossamer Bio.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
17.4%
average across 6 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
Seralutinib
Phase 3 · Pulmonary Arterial Hypertension

Full Press Release Details

SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2026-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026 .
Cantor Global Healthcare Conference
Date / Time: September 9th , at 10:55 AM ET Format: Presentation & 1x1’s Location: NYC, NY Webcast Link: Here
About Gossamer Bio
Gossamer Bio is a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260904867053/en/
For Investors and Media Bryan Giraudo, Chief Financial Officer & Chief Operating Officer Gossamer Bio Investor Relations ir@gossamerbio.com
Source: Gossamer Bio, Inc.

Frequently Asked Questions

When will Gossamer Bio present at the conference?

Gossamer Bio will present at the Cantor Global Healthcare Conference on September 9, 2026.

What is the focus of Gossamer Bio's presentation?

The presentation will focus on seralutinib for treating pulmonary hypertension.

Where is the Cantor Global Healthcare Conference held?

The conference will take place in New York City, NY.

What is seralutinib used to treat?

Seralutinib is developed for pulmonary arterial hypertension and PH-ILD.

Last updated: Sep 4, 2026